Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Int J Mol Sci ; 23(3)2022 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-35163551

RESUMO

For years, the gold standard for diagnosing Gaucher disease (GD) has been detecting reduced ß-glucocerebrosidase (GCase) activity in peripheral blood cells combined with GBA1 mutation analysis. The use of dried blood spot (DBS) specimens offers many advantages, including easy collection, the need for a small amount of blood, and simpler transportation. However, DBS has limitations for measuring GCase activity. In this paper, we recount our cross-sectional study and publish seven years of experience using DBS samples and levels of the deacylated form of glucocerebroside, glucosylsphingosine (lyso-Gb1), for GD diagnosis. Of 444 screened subjects, 99 (22.3%) were diagnosed with GD at a median (range) age of 21 (1-78) years. Lyso-Gb levels for genetically confirmed GD patients vs. subjects negative to GD diagnosis were 252 (9-1340) ng/mL and 5.4 (1.5-16) ng/mL, respectively. Patients diagnosed with GD1 and mild GBA1 variants had lower median (range) lyso-Gb1, 194 (9-1050), compared to GD1 and severe GBA1 variants, 447 (38-1340) ng/mL, and neuronopathic GD, 325 (116-1270) ng/mL (p = 0.001). Subjects with heterozygous GBA1 variants (carrier) had higher lyso-Gb1 levels, 5.8 (2.5-15.3) ng/mL, compared to wild-type GBA1, 4.9 (1.5-16), ng/mL (p = 0.001). Lyso-Gb1 levels, median (range), were 5 (2.7-10.7) in heterozygous GBA1 carriers with Parkinson's disease (PD), similar to lyso-Gb1 levels in subjects without PD. We call for a paradigm change for the diagnosis of GD based on lyso-Gb1 measurements and confirmatory GBA1 mutation analyses in DBS. Lyso-Gb1 levels could not be used to differentiate between heterozygous GBA1 carriers and wild type.


Assuntos
Biomarcadores/sangue , Doença de Gaucher/diagnóstico , Glucosilceramidase/genética , Psicosina/análogos & derivados , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Estudos Transversais , Detecção Precoce de Câncer , Feminino , Doença de Gaucher/sangue , Doença de Gaucher/genética , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Mutação , Psicosina/sangue , Adulto Jovem
2.
J Cell Mol Med ; 24(17): 9726-9736, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32767726

RESUMO

Gaucher disease (GD) is a genetic disease with mutations in the GBA gene that encodes glucocerebrosidase causing complications such as anaemia and bone disease. GD is characterized by accumulation of the sphingolipids (SL) glucosylceramide (GL1), glucosylsphingosine (Lyso-GL1), sphingosine (Sph) and sphingosine-1-phosphate (S1P). These SL are increased in the plasma of GD patients and the associated complications have been attributed to the accumulation of lipids in macrophages. Our recent findings indicated that red blood cells (RBCs) and erythroid progenitors may play an important role in GD pathophysiology. RBCs abnormalities and dyserythropoiesis have been observed in GD patients. Moreover, we showed higher SL levels in the plasma and in RBCs from untreated GD patients compared with controls. In this study, we quantified SL in 16 untreated GD patients and 15 patients treated with enzyme replacement therapy. Our results showed that the treatment significantly decreases SL levels in the plasma and RBCs. The increased SL content in RBCs correlates with abnormal RBC properties and with markers of disease activity. Because RBCs lack glucocerebrosidase activity, we investigated how lipid overload could occur in these cells. Our results suggested that SL overload in RBCs occurs both during erythropoiesis and during its circulation in the plasma.


Assuntos
Eritrócitos/metabolismo , Doença de Gaucher/sangue , Glucosilceramidase/genética , Esfingolipídeos/sangue , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Criança , Pré-Escolar , Eritropoese/genética , Feminino , Doença de Gaucher/genética , Doença de Gaucher/patologia , Humanos , Lisofosfolipídeos/sangue , Macrófagos/metabolismo , Masculino , Pessoa de Meia-Idade , Psicosina/análogos & derivados , Psicosina/sangue , Esfingosina/análogos & derivados , Esfingosina/sangue , Adulto Jovem
3.
J Inherit Metab Dis ; 43(3): 558-563, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-31707742

RESUMO

Gaucher disease (GD) is an inherited metabolic disorder characterised by impaired catabolism of the glycosphingolipid, glucosylceramide. The deacetylated derivative, glucosylsphingosine (GluSph, lyso-Gb1) has materialised as a biomarker for GD. Further appraisal of the clinical utility of GluSph is required in terms of its prognostic power to inform disease course and pre-symptomatic testing. In this study, we show that plasma GluSph concentrations are significantly higher in GD patients with neuronopathic disease compared with non-neuronopathic disease, even in the neonatal period. A neonate diagnosed at 1 day of age (homozygous for N370S) due to an affected older sibling, returned GluSph of 70 nmol/L compared with 1070-2620 nmol/L for four neuronopathic patients diagnosed <20 days of age. Given this result shows promise for newborn screening, we developed a rapid, simple, and robust assay for GluSph in dried filter paper blood spots (DBS) and were able to detect 23 GD patients from 220 unaffected individuals. Neuronopathic GD patients also had significantly higher DBS concentrations of GluSph than their non-neuronopathic counterparts. We went on to measure GluSph in tissue extracts prepared from chorionic villus sampling and confirmed concentrations were undetectable in unaffected tissue but elevated in GD tissue demonstrating utility in the prenatal setting. Additionally, GluSph is a pharmacodynamic biomarker, revealing a precipitous drop following initiation of enzyme replacement therapy. In conclusion, GluSph is a reliable and specific biomarker for GD and shows promise for prenatal diagnosis and DBS screening programmes.


Assuntos
Teste em Amostras de Sangue Seco/métodos , Doença de Gaucher/sangue , Psicosina/análogos & derivados , Adolescente , Adulto , Biomarcadores/sangue , Criança , Pré-Escolar , Cromatografia Líquida , Feminino , Doença de Gaucher/diagnóstico , Humanos , Lactente , Recém-Nascido , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Gravidez , Diagnóstico Pré-Natal , Psicosina/sangue , Espectrometria de Massas em Tandem , Adulto Jovem , beta-Glucosidase/metabolismo
4.
Br J Ophthalmol ; 103(3): 315-326, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30612093

RESUMO

Gaucher disease (GD) results from a deficiency of glucocerebrosidase activity and the subsequent accumulation of the enzyme's metabolites, principally glucosylsphingosine and glucosylceramide. There are three principal forms: Type I, which is the most common, is usually considered non-neuronopathic. Type II, III and IIIc manifest earlier and have neurological sequelae due to markedly reduced enzyme activity. Gaucher's can be associated with ophthalmological sequelae but these have not been systematically reviewed. We therefore performed a comprehensive literature review of all such ophthalmic abnormalities associated with the different types of Gaucher disease. We systematically searched the literature (1950 - present) for functional and structural ocular abnormalities arising in patients with Gaucher disease and found that all subtypes can be associated with ophthalmic abnormalities; these range from recently described intraocular lesions to disease involving the adnexae, peripheral nerves and brain. In summary, Gaucher can affect most parts of the eye. Rarely is it sight-threatening; some but not all manifestations are amenable to treatment, including with enzyme replacement and substrate reduction therapy. Retinal involvement is rare but patients with ocular manifestations should be monitored and treated early to reduce the risk of progression and further complications. As Gaucher disease is also associated with Parkinsons disease and may also confer an increased risk of malignancy (particularly haematological forms and melanoma), any ocular abnormalities should be fully investigated to exclude these potential underlying conditions.


Assuntos
Oftalmopatias/diagnóstico , Doença de Gaucher/diagnóstico , Doenças por Armazenamento dos Lisossomos/diagnóstico , Oftalmopatias/classificação , Oftalmopatias/etiologia , Doença de Gaucher/classificação , Doença de Gaucher/etiologia , Glucosilceramidas/sangue , Humanos , Doenças por Armazenamento dos Lisossomos/classificação , Doenças por Armazenamento dos Lisossomos/etiologia , Fenótipo , Psicosina/análogos & derivados , Psicosina/sangue
5.
Mol Genet Metab ; 121(3): 271-278, 2017 07.
Artigo em Inglês | MEDLINE | ID: mdl-28579020

RESUMO

Newborn screening (NBS) for Krabbe disease, a rare neurodegenerative disorder caused by deficient galactocerebrosidase (GALC) enzyme activity, has recently been implemented in a number of US states. However, the spectrum of phenotypic manifestations associated with deficient GALC activity complicates the management of screen-positive newborns and underscores the need to identify clinically relevant biomarkers. Earlier studies with a small number of patients identified psychosine, a substrate of the GALC enzyme, as a potential biomarker for Krabbe disease. In this study, we provide, for the first time, longitudinal data on dried blood spot (DBS) psychosine concentrations in different Krabbe disease phenotypes for both untreated patients and those treated with hematopoietic stem cell transplantation (HSCT). Our cohort included patients previously identified by NBS to be at high risk to develop Krabbe disease. Substantially elevated DBS psychosine concentration during the newborn period was found to be a highly specific marker for infantile Krabbe disease. This finding supports the use of DBS psychosine concentration as a second-tier NBS test to aid in the identification of patients who require urgent evaluation for HSCT. In addition, longitudinal assessments showed that both natural disease progression and treatment with HSCT were associated with decreases in DBS psychosine concentrations. Based on these findings we provide recommendations for the interpretation of psychosine concentrations in DBS specimens collected during the first year of life. Future studies should aim to better delineate the relationship between DBS psychosine concentration and disease onset in patients with later-onset forms of Krabbe disease.


Assuntos
Biomarcadores/sangue , Leucodistrofia de Células Globoides/diagnóstico , Psicosina/sangue , Adolescente , Criança , Pré-Escolar , Progressão da Doença , Teste em Amostras de Sangue Seco , Humanos , Lactente , Recém-Nascido , Leucodistrofia de Células Globoides/tratamento farmacológico , Triagem Neonatal , Fenótipo , Espectrometria de Massas em Tandem
6.
J Inherit Metab Dis ; 38(5): 923-9, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25762404

RESUMO

BACKGROUND: Newborn screening (NBS) for Krabbe disease (KD) in New York and Missouri is conducted by measuring galactocerebrosidase (GALC) activity using tandem mass spectrometry (MS/MS). These NBS efforts have shown that the incidence of KD is unexpectedly low (1:400,000) while many individuals (ca. 1:6000) with reduced GALC activity and genotypes of uncertain significance are detected and subjected to follow up testing. Psychosine (PSY) is a putative marker of KD progression and can be measured in dried blood spots (DBS). We sought to determine the role that PSY levels play in NBS for KD, follow up, and treatment monitoring. METHODS: PSY was eluted from DBS with methanol containing N,N-dimethyl-D-erythro-sphingosine as internal standard (IS). Liquid chromatography-MS/MS was conducted over 17 minutes in the multiple reaction monitoring positive mode to follow the precursor to product species transitions for PSY and IS. Separation of the structural isomers PSY and glucosylsphingosine was accomplished by hydrophilic interaction liquid chromatography. RESULTS: Pre-analytical and analytical factors were studied and revealed satisfactory results. PSY was also measured in DBS collected from controls (range: <8 nmol/L, N = 220), KD patients at various disease stages (range: 8-112, N = 26), and GALC mutation carriers (range: <15 nmol/L, N = 18). CONCLUSIONS: PSY measurement in DBS could serve as a 2nd tier assay in NBS for KD, simplify and reduce the cost of follow up protocols, help determine disease progression, and be used to monitor KD patients following hematopoietic stem cell transplantation. However, additional chronological measurements of PSY in KD patients are required to confirm these possibilities.


Assuntos
Teste em Amostras de Sangue Seco , Leucodistrofia de Células Globoides/diagnóstico , Triagem Neonatal/métodos , Psicosina/sangue , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Teste em Amostras de Sangue Seco/normas , Humanos , Lactente , Recém-Nascido , Leucodistrofia de Células Globoides/sangue , Limite de Detecção , Pessoa de Meia-Idade , Triagem Neonatal/normas , Psicosina/análise , Melhoria de Qualidade , Valores de Referência , Reprodutibilidade dos Testes , Adulto Jovem
7.
J Pathol ; 231(1): 88-97, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23775597

RESUMO

Multiple myeloma and B cell lymphoma are leading causes of death in Gaucher's disease but the nature of the stimulus driving the often noted clonal expansion of immunoglobulin-secreting B cells and cognate lymphoid malignancy is unknown. We investigated the long-term development of B cell malignancies in an authentic model of non-neuronopathic Gaucher's disease in mice: selective deficiency of ß-glucocerebrosidase in haematopoietic cells [Gba(tm1Karl/tm1Karl)Tg(Mx1-cre)1Cgn/0, with excision of exons 9-11 of the murine GBA1 gene, is induced by poly[I:C]. Mice with Gaucher's disease showed visceral storage of ß-glucosylceramide and greatly elevated plasma ß-glucosylsphingosine [median 57.9 (range 19.8-159) nm; n = 39] compared with control mice from the same strain [median 0.56 (range 0.04-1.38) nm; n = 29] (p < 0.0001). Sporadic fatal B cell lymphomas developed in 11 of 21 GD mice (6-24 months) but only two of eight control animals developed tumours by age 24 months. Unexpectedly, most mice with overt lymphoma had absent or few Gaucher cells but local inflammatory macrophages were present. Eleven of 39 of Gaucher mice developed monoclonal gammopathy, but in the control group only one animal of 25 had clonal immunoglobulin abnormalities. Seven of 10 of the B cell lymphomas were found to secrete a monoclonal paraprotein and the lymphomas stained intensely for pan-B cell markers; reactive T lymphocytes were also present in tumour tissue. In the Gaucher mouse strain, it was notable that, as in patients with this disease, CD138(+) plasma cells frequently surrounded splenic macrophages engorged with glycosphingolipid. Our strain of mice, with inducible deficiency of ß-glucocerebrosidase in haematopoietic cells and a high frequency of sporadic lethal B cell malignancies, faithfully recapitulates human Gaucher's disease: it serves as a tractable model to investigate the putative role of bioactive sphingolipids in the control of B cell proliferation and the pathogenesis of myelomatosis-the most prevalent human cancer associated with this disorder.


Assuntos
Modelos Animais de Doenças , Doença de Gaucher/complicações , Linfoma de Células B/complicações , Mieloma Múltiplo/complicações , Animais , Células da Medula Óssea/metabolismo , Células da Medula Óssea/patologia , Células Clonais , Feminino , Doença de Gaucher/metabolismo , Doença de Gaucher/patologia , Glucosilceramidase/deficiência , Glucosilceramidase/genética , Glucosilceramidas/metabolismo , Humanos , Imunoglobulinas/metabolismo , Linfoma de Células B/metabolismo , Linfoma de Células B/patologia , Macrófagos/metabolismo , Macrófagos/patologia , Masculino , Camundongos , Camundongos Transgênicos , Mieloma Múltiplo/metabolismo , Mieloma Múltiplo/patologia , Paraproteinemias/complicações , Paraproteinemias/metabolismo , Paraproteinemias/patologia , Psicosina/análogos & derivados , Psicosina/sangue , Baço/metabolismo , Baço/patologia , Sindecana-1/metabolismo , Linfócitos T/metabolismo , Linfócitos T/patologia
8.
Blood ; 118(16): e118-27, 2011 Oct 20.
Artigo em Inglês | MEDLINE | ID: mdl-21868580

RESUMO

Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, leads to prominent glucosylceramide accumulation in lysosomes of tissue macrophages (Gaucher cells). Here we show glucosylsphingosine, the deacylated form of glucosylceramide, to be markedly increased in plasma of symptomatic nonneuronopathic (type 1) Gaucher patients (n = 64, median = 230.7 nM, range 15.6-1035.2 nM; normal (n = 28): median 1.3 nM, range 0.8-2.7 nM). The method developed for mass spectrometric quantification of plasma glucosylsphingosine is sensitive and robust. Plasma glucosylsphingosine levels correlate with established plasma markers of Gaucher cells, chitotriosidase (ρ = 0.66) and CCL18 (ρ = 0.40). Treatment of Gaucher disease patients by supplementing macrophages with mannose-receptor targeted recombinant glucocerebrosidase results in glucosylsphingosine reduction, similar to protein markers of Gaucher cells. Since macrophages prominently accumulate the lysoglycosphingolipid on glucocerebrosidase inactivation, Gaucher cells seem a major source of the elevated plasma glucosylsphingosine. Our findings show that plasma glucosylsphingosine can qualify as a biomarker for type 1 Gaucher disease, but that further investigations are warranted regarding its relationship with clinical manifestations of Gaucher disease.


Assuntos
Doença de Gaucher/sangue , Doença de Gaucher/tratamento farmacológico , Glucosilceramidase/uso terapêutico , Psicosina/análogos & derivados , Quimiocinas CC/sangue , Terapia de Reposição de Enzimas , Terapia Enzimática , Feminino , Doença de Gaucher/enzimologia , Doença de Gaucher/genética , Genótipo , Glucosilceramidase/genética , Hexosaminidases/sangue , Humanos , Macrófagos/citologia , Masculino , Fenótipo , Psicosina/sangue , Proteínas Recombinantes/genética , Proteínas Recombinantes/uso terapêutico , Espectrometria de Massas por Ionização por Electrospray
9.
Ann Neurol ; 42(4): 613-21, 1997 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-9382473

RESUMO

We prospectively evaluated the clinical and biochemical responses to enzyme-replacement therapy (ERT) with macrophage-targeted glucocerebrosidase (Ceredase) infusions in 5 patients (age, 3.5-8.5 years) with type 3 Gaucher's disease. The patients were followed for up to 5 years. Enzyme dosage ranged from 120 to 480 U/kg of body weight/month. Systemic manifestations of the disease regressed in all patients. Neurological deficits remained stable in 3 patients and slightly improved in 1. One patient developed myoclonic encephalopathy. Cognitive deterioration occurred in 1 patient and electroencephalographic deterioration in 2. Sequential cerebrospinal fluid (CSF) samples were obtained during the first 3 years of treatment in 3 patients and were analyzed for biochemical markers of disease burden. Glucocerebroside and psychosine levels were not elevated in these specimens, whereas chitotriosidase and quinolinic acid were elevated in 2 patients. Progressive decrease in the CSF levels of these latter macrophage markers during 3 years of treatment implies a decreased number of Gaucher cells in the cerebral perivascular space. Similar changes were not observed in the patient who had a poor neurological outcome. In conclusion, ERT reverses systemic manifestations of type 3 Gaucher's disease and appears to reduce the burden of Gaucher cells in the brain-CSF compartment in some patients.


Assuntos
Doença de Gaucher/tratamento farmacológico , Glucosilceramidase/administração & dosagem , Macrófagos/enzimologia , Anticorpos/sangue , Biomarcadores , Criança , Pré-Escolar , Eletroencefalografia , Potenciais Evocados Auditivos do Tronco Encefálico , Feminino , Doença de Gaucher/diagnóstico , Doença de Gaucher/fisiopatologia , Glucosilceramidase/efeitos adversos , Glucosilceramidase/imunologia , Hexosaminidases/sangue , Hexosaminidases/líquido cefalorraquidiano , Humanos , Proteína Antagonista do Receptor de Interleucina 1 , Interleucina-1/sangue , Interleucina-1/líquido cefalorraquidiano , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Masculino , Exame Neurológico , Testes Neuropsicológicos , Nitritos/sangue , Nitritos/líquido cefalorraquidiano , Estudos Prospectivos , Psicosina/sangue , Psicosina/líquido cefalorraquidiano , Ácido Quinolínico/sangue , Ácido Quinolínico/líquido cefalorraquidiano , Receptores de Interleucina-1/antagonistas & inibidores , Sialoglicoproteínas/sangue , Sialoglicoproteínas/líquido cefalorraquidiano , Fator de Crescimento Transformador beta/sangue , Fator de Crescimento Transformador beta/líquido cefalorraquidiano
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA